OGXI Share Price

Open 0.35 Change Price %
High 0.37 1 Day 0.00 0.00
Low 0.35 1 Week 0.00 0.00
Close 0.35 1 Month -0.02 -5.41
Volume 63438 1 Year -0.54 -60.67
52 Week High 1.32
52 Week Low 0.33
OGXI Important Levels
Resistance 2 0.37
Resistance 1 0.36
Pivot 0.36
Support 1 0.34
Support 2 0.33
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
FTR 1.46 12.31%
FTR 1.46 12.31%
SUSQ 14.20 -0.77%
CSCO 31.21 -0.54%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.08 60.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
CMLS 0.49 25.64%
OTT 2.39 25.13%
EVEP 1.30 18.18%
ARNA 1.33 15.65%
INVE 5.72 14.86%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)

OGXI Technical Analysis 5
As on 19th May 2017 OGXI Share Price closed @ 0.35 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.57 & Strong Sell for SHORT-TERM with Stoploss of 0.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
OGXI Target for May
1st Target up-side 0.44
2nd Target up-side 0.48
3rd Target up-side 0.52
1st Target down-side 0.32
2nd Target down-side 0.28
3rd Target down-side 0.24
OGXI Other Details
Segment EQ
Market Capital 178379728.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncogenex.com
OGXI Address
OGXI
1522- 217th Place SE
Suite 100
Bothell, WA 98021
United States
Phone: 425-686-1500
OGXI Latest News
Interactive Technical Analysis Chart OncoGenex Pharmaceuticals Inc. ( OGXI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on OncoGenex Pharmaceuticals Inc.
OGXI Business Profile
OncoGenex Pharmaceuticals, Inc. (OncoGenex) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The Company has four product candidates in its pipeline: custirsen, OGX-427, OGX-225 and CSP-9222. Of the product candidates in its pipeline, custirsen and OGX-427 are clinical-stage assets. The Company�s product candidates custirsen, OGX-427, and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote survival of tumor cells, and are over-produced in response to a variety of cancer treatments. Product candidate CSP-9222 is the lead compound from a family of caspase activators that have been in-licensed from Bayer and demonstrate activation of programmed cell death in pre-clinical models.